Injection of adeno-associated virus (AAV) into the cerebrospinal fluid (CSF) offers a means
to achieve widespread transgene delivery to the central nervous system, where the doses …

The present study builds on previous work showing that infusion of adeno-associated virus
type 9 (AAV9) into the cisterna magna (CM) of nonhuman primates resulted in widespread …

Adeno-associated virus serotype 9 (AAV9) vectors have recently been shown to transduce
cells throughout the central nervous system of nonhuman primates when injected into the …

Adeno-associated viral (AAV) vectors have shown promise as a platform for gene therapy of
neurological disorders. Achieving global gene delivery to the central nervous system (CNS) …

The identification of the most efficient method for whole central nervous system targeting that
is translatable to humans and the safest route of adeno-associated virus (AAV) …

Effective gene delivery to the central nervous system (CNS) is vital for development of novel
gene therapies for neurological diseases. Adeno-associated virus (AAV) vectors have …

Gene therapy clinical trials for neurological disorders are ongoing using intrathecal injection
of adeno-associated virus (AAV) vector directly into the cerebral spinal fluid. Preliminary …

The present study was designed to characterize transduction of non-human primate brain
and spinal cord with AAV5 viral vector after parenchymal delivery. AAV5-CAG-GFP (1× 10 …

Non-human primates (NHPs) are a preferred animal model for optimizing adeno-associated
virus (AAV)-mediated CNS gene delivery protocols before clinical trials. In spite of its …

Adeno-associated viral (AAV) vectors have become the primary delivery agent for somatic
gene transfer into the central nervous system (CNS). To date, AAV-mediated gene delivery …